Across 6 studies, all reported moderate beneficial effects of Lactobacillus acidophilus L-92 on reducing atopic dermatitis severity, with 4 of 6 findings being statistically significant. The evidence is strongest in children and adults with clinically diagnosed atopic dermatitis. Study durations and doses were not consistently reported, precluding identification of a typical effective dose or treatment period.
Caveats: Available evidence is overwhelmingly positive (6 of 6 beneficial), but clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). The evidence base is small (only 6 studies) — conclusions should be considered preliminary. Doses and study durations were not reported in the available data, limiting the ability to specify effective regimens.
No adverse events were reported during the study period.
from: Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with aThe treatment significantly reduced SCORAD score (WMD = -3.75, 95% CI: -5.08 to -2.42).
Compared with the placebo group, the L-92 group showed significant decreases in investigator global assessment, eczema area and severity index, and scoring atopic dermatitis.
Pooled analysis using a random-effects model (Hedges' g ≈ 0.65, p < 0.05) indicated a moderate to large improvement in AD severity with probiotic therapy.
Orally administered L-92 significantly ameliorated the symptoms of AD in Japanese children.
Lactobacillus acidophilus L-92 has been reported to improve clinical symptoms in patients with atopic dermatitis.
Studies suggest that L. acidophilus L-92 may help alleviate atopic dermatitis, contributing to improved skin condition and quality of life.